Activation of dendritic cells by tumor cell death

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1218-1219

  Cirone, Mara ^a   Renzo, Livia Di ^a   Lotti, Lavinia V ^a   Conte, Valeria ^a   Trivedi, Pankaj ^a   Santarelli, Roberta ^a   Gonnella, Roberta ^a   Frati, Luigi ^a   Faggioni, Alberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

AG490; Bortezomib; CD91; DC; PEL

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CALRETICULIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CELL ACTIVATION; CELL DEATH; CELL MATURATION; COCULTURE; CROSS PRESENTATION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PHAGOCYTOSIS; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR CELL DEATH;

EID: 84881036485     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20428     Document Type: Article

References (10)

1. Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, et al. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 2011; 30:71-82; PMID:21298323; http://dx.doi.org/10.1007/s10555-011-9283-2.
2. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805:53-71; PMID:19720113.
3. Griffith TS, Ferguson TA. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity 2011; 35:456-66; PMID:22035838; http://dx.doi.org/10.1016/j.immuni.2011.08.011.
4. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30:61-9; PMID:21249425; http://dx.doi.org/10.1007/s10555-011-9273-4.
5. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemo-therapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/sci-ence.1208347.
6. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, et al. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One 2012; 7:31732; PMID:22412839; http://dx.doi.org/10.1371/journal.pone.0031732.
7. Melillo JA, Song L, Bhagat G, Blazquez AB, Plumlee CR, Lee C, et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol 2010; 184:2638-45; PMID:20124100; http://dx.doi.org/10.4049/jimmunol.0902960.
8. Zhang Y, Morgan MJ, Chen K, Choksi S, Liu ZG. Induction of autophagy is essential for monocyte-mac-rophage differentiation. Blood 2012; 119:2895-905; PMID:22223827; http://dx.doi.org/10.1182/blood-2011-08-372383.
9. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70 and calreticulin. Immunity 2001; 14:303-13; PMID:11290339; http://dx.doi.org/10.1016/S1074-7613(01)00111-X.
10. Stebbing J, Gazzard B, Kim L, Portsmouth S, Wildfire A, Teo I, et al. The heat-shock protein receptor CD91 is upregulated in monocytes of HIV-1-infected "true" long-term nonprogressors. Blood 2003; 101:4000-4; PMID:12531796; http://dx.doi.org/10.1182/blood-2002-11-3353.